Durvalumab,Abbexa,abx831328
Durvalumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD274, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0. 1 and 0. 04 nM, respectively. （适用于人源及非人源化小鼠）
Host
Human
Reactivity
Human
Application
ELISA, WB
Conjugate
Unconjugated
Platform ID
BAB238001781
Abbexa
Contact
Tel: +44 (0) 1223 755950
Fax: +44 (0) 1223 755951
Email:
Product Specifications
Specifications
NameDurvalumab
Cat. No.abx831328
HostHuman
IsotypeIgG1 Kappa
ReactivityHuman
ConjugationUnconjugated
ApplicationELISA, WB
Working DilutionsOptimal dilutions/concentrations should be determined by the end user.
ClonalityMonoclonal
ConcentrationBatch-dependent, typically between 0.5-2.0 mg/ml.
TargetCD274
PurityPurified from cell culture supernatants by Protein A/G chromatography.
Appearance/FormLiquid
Formulation0.01 M PBS. pH 7.4.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Regulatory StatusResearch Use Only
Category Paths
- Products>Primary Antibodies>Biosimilar Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.